Jeremy Nathans: A life in science decoding the machinery of sight
Howard Hughes Medical Institute
image: HHMI Investigator Jeremy Nathans in his lab at Johns Hopkins University. Over nearly 40 years, his work has spanned color vision, retinal disease, and the Frizzled family of receptors.
Credit: Credit: Steve Ruark/AP Images for Howard Hughes Medical Institute
Key Takeaways:
- Nathans’ work has traced the genetic and molecular roots of vision, from isolating the genes underlying human color vision to helping uncover the causes of several retinal diseases.
- A chance discovery in his own lab led Nathans to a family of receptors called Frizzled, which controls the orientation of cells and multicellular structures throughout the body.
- Following Frizzled receptors into the retina, Nathans discovered a molecular signal that guides blood vessel growth into the eye and brain and controls the development and maintenance of the blood-brain barrier — research that led to an experimental therapy now in a late-stage clinical trial for diabetic retinopathy.
- As he steps back from active research, Nathans is focused on supporting early-career scientists through teaching and mentoring.
In his nearly forty years as an HHMI Investigator, Jeremy Nathans has made discoveries across an unusually wide range of biomedical science. His research spans color vision and retinal disease; the Frizzled family of receptors; and molecular signaling in the blood-brain barrier.
“My research program has been pretty eclectic,” Nathans says. “Vision research has been our central theme, but my students and I have enjoyed pursuing scientific questions beyond our comfort zone.”
That instinct has pulled him into seemingly unrelated corners of biology — developmental signaling, vascular biology, human genetics, structural biology, and neuroscience — yet each new thread has eventually looped back to the eye, the organ where his career began.
The Code for Color
Long before he ran his own lab, Nathans had a front-row seat to scientific excellence: his father, Daniel Nathans, was a Nobel laureate and later became an HHMI Investigator. His parents never pushed their children toward any particular path — Nathans’ two brothers became historians — but Nathans gravitated to science early, landing at Baltimore Polytechnic Institute, a magnet high school for math and science, and then MIT for undergraduate degrees in chemistry and biology.
From there, Nathans pursued an MD-PhD at Stanford, where he conducted his PhD thesis research in the laboratory of David Hogness, one of the world’s preeminent Drosophila molecular geneticists. During this time, Nathans attended lectures by Denis Baylor and Lubert Stryer on the vertebrate retina — a system he found so beautiful that it changed the course of his research. In the Hogness lab, he’d learned how to isolate and sequence genes. He realized that this technology could answer fundamental, exciting questions around human vision.
Nathans set out to understand the relationship between the light receptor proteins in rods, which mediate night vision, and those in cones, which mediate color vision. He theorized that, like the alpha and beta chains of hemoglobin, the different types of light receptors stemmed from a common ancestor and retained similar structures, despite their sensitivity to different wavelengths of light. Working initially with cow eyes — which he collected from a local slaughterhouse — he first isolated the gene for rhodopsin, the rod receptor gene. That was followed over the next several years by the three human cone receptor genes: the long wavelength (red), middle wavelength (green), and short wavelength (blue) light.
These experiments led to an unexpected discovery: the genes for red and green receptors sit side-by-side on the X-chromosome and are nearly identical in sequence. Nathans showed that their tendency to recombine with each other during meiosis is the basis for the well-known inherited variation in red-green color vision.
Mapping Retinal Diseases, Gene by Gene
After one year as a postdoctoral fellow at Genentech, Nathans launched his own lab at Johns Hopkins Medical School. A joint appointment at the Wilmer Eye Institute brought him into closer contact with patients and families affected by serious visual impairments, and he decided to redirect part of his research program to help them.
He started with retinitis pigmentosa (RP). Nathans showed that mutations in rhodopsin — a gene he knew well from his color-vision work — accounted for roughly one quarter of autosomal dominant RP cases. (Ted Dryja at Harvard made the same finding independently.) Using cell culture and transgenic mice, Nathans’ lab then showed how those mutations caused disease.
From there, Nathans turned to early onset macular degeneration. First, he and his collaborators helped uncover the cause of Stargardt disease, showing that it arises from a malfunctioning transporter, ABCR/ABCA4, that shuttles light-sensing molecules within the eye.
Then, Nathans and his longtime colleague King-Wai Yau turned to vitelliform macular dystrophy (VMD), digging into decades-old clinical literature describing an unexplained defect in an obscure ion current in patients’ eyes. Working together, the two labs showed that the disease gene codes for a novel anion channel — a protein that forms a pore in the cell membrane, allowing negatively charged ions to flow in or out and generate an electrical current. Others have since established a cryo-EM structure of the channel, and early efforts are underway to develop corrective drugs.
Finding Frizzled
To identify the Stargardt disease gene, the Nathans lab had used new automated technologies to sequence libraries of DNA copies of thousands of mRNAs from human retinas. They analyzed those sequences using computational genomics, then still in its infancy. Nathans and his students hoped to discover novel genes that could point them in new research directions.
One of their discoveries — a large family of integral membrane proteins called Frizzled — would change the course of his career. Fly geneticists had already identified the frizzled gene in Drosophila, showing that when it was mutated, a fly’s tiny hairs— normally uniform in orientation — pointed every which way, giving the insect a “frizzled” look.
Nathans’ team found ten Frizzled genes in the mammalian genome. He then reached out to fellow HHMI Investigator Roel Nusse, who had spent years studying a large family of secreted proteins called Wnt, known to guide embryonic development but still missing their receptors. The two labs teamed up and confirmed what Nathans suspected: Frizzleds were the missing Wnt receptors.
From Gene to Clinical Trial
When Nathans began investigating Frizzled’s functions, he hoped the findings would connect to retinal development and disease — and they did. Knocking out the Frizzled-4 gene produced a dramatic disruption in blood vessel growth in the retina, leaving it without a capillary network.
Around the same time, a mouse model of Norrie disease — a blinding disorder caused by mutations that disable a protein called Norrin — revealed an identical vascular defect. That similarity led Nathans to test whether Norrin was an alternate ligand for Frizzled-4, alongside the Wnts already known to activate it. It was: Norrin bound Frizzled-4 with high affinity, and activated signaling in the same way that Wnt-Frizzled binding did. They concluded that Norrie disease occurs when that signaling pathway is defective.
Nathans found that the Norrin/Frizzled-4 signal converges on a protein called beta-catenin, which controls how blood vessels grow into the retina and brain — and how they build the blood-brain barrier that protects the central nervous system.
That basic science insight has since moved toward the clinic. Structural work by fellow HHMI Investigator Chris Garcia paved the way for the design of synthetic molecules that switch beta-catenin on, leading to the development of drug candidates that activate Frizzled-4, one of which is now being tested in patients with diabetic retinopathy. Nathans, who serves as a scientific advisor on the project, notes that this drug candidate is currently in a large Phase 3 trial.
Passing the Torch
Nathans is now looking toward the next phase of his own career. Nathans is reluctant to use the “r” word — retirement — but he is winding down his research and his HHMI tenure. “Research funding is a zero-sum game, and I don’t want to consume more resources,” he explains. “Some older scientists are still full of new ideas and doing amazing work, but I think my path is now to help our younger colleagues fulfill their ambitions.”
Nathans is excited to expand his commitment to teaching, which he has always loved, both in-person and via the internet. Nathans will also remain involved in biotechnology, which he sees as an essential path to helping patients.
Above all, he’ll be guided by the same sense of purpose that has directed his research career, summed up in three words: “To be useful.”
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.